Australian technology start-up 4DX has attracted one of the biggest names in global oncology as its latest Board member.
LONDON, Nov. 30, 2016 /PRNewswire/ -- Robert A. Figlin, MD, FACP, joins the 4Dx board on December 1st. Dr Figlin is Deputy Director of the Integrated Oncology Service Line. He also serves as the Deputy Director at the Samuel Oschin Comprehensive Cancer Institute, part of the world-renowned Cedars-Sinai Medical Center in Los Angeles and is Director of the Hematology Oncology Division at the institute, where he is in charge of integrating research and clinical strategies across all the Cedars-Sinai campuses.
Since his arrival at Cedars- Sinai, he established the Experimental Therapeutics Program and successfully recruited clinical research staff in critical specialty areas such as breast cancer, bone marrow transplant, gastrointestinal oncology, genitourinary oncology, survivorship, and cancer biology.
Dr Figlin says, "4Dx has developed some of the most promising and exciting technology I've ever seen in the fight against disease. It will be a privilege to be able to use my medical and business experience to assist the company through this phase of its growth."
Dr Figlin co-founded Agensys - an early stage biotechnology company focussed on developing novel therapies for cancer. The company has since been sold to Astellas Pharmaceuticals as part of a nine-figure deal.
4Dx founder and chair, Andreas Fouras, says, "Bob Figlin brings unparalleled experience and expertise in cancer therapies to 4Dx, where enhanced cancer treatment is among our first priorities. Bob brings a vast medical knowledge and adds enormous capacity to our board's business decision making capacity."
Lung cancer is the biggest killer of all cancers and the current standard treatments of chemotherapy and radiotherapy have devastating effects on the lungs. 4Dx technology is non-invasive and will positively impact the way medical professionals are able to diagnose, and treat their patients.
"4Dx is undergoing significant acceleration and is thrilled to have a clinician, researcher and entrepreneurial thinker in Bob Figlan join our team."
"This revolutionary technology and the development of unique software to generate moving, ultra-high-resolution images of motion and airflow in lung tissue enables clinicians to view and measure abnormal lung function at the earliest stages of disease in a way that has not been possible before now."
As well as their association with Cedars- Sinai, 4Dx has also created partnerships with other leading hospitals such as the Cleveland Clinic and the Children's Hospital Los Angeles in the US, and The Alfred and Peter Mac in Australia.
4Dx is a software company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders, including, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.
The unique 4Dx technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service scans deliver much more complete results, showing the subtlest variations in lung function down to the finest details, using lower levels of radiation than traditional methods.
Respiratory diagnosis is a $25 billion p.a global industry that 4Dx aims to disrupt and grow through technology that provides clinicians with greater insights into diseases of the lung.
4Dx will bring about a step change in lung health by providing better information to doctors and patients.
0407 162 530